George Abercrombie - Theseus Pharmaceuticals President
THRXDelisted Stock | USD 4.06 0.00 0.00% |
President
Mr. George B. Abercrombie is Senior Vice President Corporationrationrate Partnerships Commercial of the Company. Mr. George B. Abercrombie RPh MBA joined Innoviva Inc. in June 2014. Prior to joining Innoviva Mr. Abercrombie served as the President and Chief Executive Officer of HoffmannLa Roche Inc. from 2001 to 2009 where he was responsible for the US and Canadian business divisions. From 1993 to 2001 Mr. Abercrombie worked at Glaxo and its successor companies including as Senior Vice President of Commercial Operations for Glaxo Wellcome Inc. He is the Chairman of the Board of BioCryst Pharmaceuticals Inc. and also serves as a board member of numerous other healthcarerelated organizations including Project Hope and the North Carolina GlaxoSmithKline Foundation since 2014.
Age | 60 |
Tenure | 10 years |
Professional Marks | MBA |
Phone | 857 400 9491 |
Web | https://theseusrx.com |
Theseus Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1789) % which means that it has lost $0.1789 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2555) %, meaning that it created substantial loss on money invested by shareholders. Theseus Pharmaceuticals' management efficiency ratios could be used to measure how well Theseus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 3.98 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Theseus Pharmaceuticals has a current ratio of 26.99, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Theseus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Theseus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Theseus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Theseus to invest in growth at high rates of return. When we think about Theseus Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | PRESIDENT Age | ||
Justin Paul | TFI International | N/A | |
Andrea Greenberg | Sphere Entertainment Co | 65 | |
Scott Felenstein | National CineMedia | 55 | |
David GranvilleSmith | Sphere Entertainment Co | 57 | |
Christopher Brooks | Old Dominion Freight | 53 | |
Kevin Freeman | Old Dominion Freight | 65 | |
David Bates | Old Dominion Freight | 53 | |
Ross Parr | Old Dominion Freight | 52 | |
Eric Anson | TFI International | N/A | |
Sarah Hilty | National CineMedia | 47 | |
Patrick Collins | NETGEAR | 44 | |
Michael Werdann | NETGEAR | 56 | |
Larry Fuaco | TFI International | N/A | |
Clifford Marks | National CineMedia | 56 | |
Tamesa Rogers | NETGEAR | 50 | |
Craig Abrahams | Playtika Holding Corp | 47 | |
Kristen Fess | TFI International | N/A | |
Kevin Tait | TFI International | N/A | |
CPA CMA | TFI International | N/A | |
Lawrence Snapp | National CineMedia | 78 | |
John Harrington | TFI International | N/A |
Management Performance
Return On Equity | -0.26 | |||
Return On Asset | -0.18 |
Theseus Pharmaceuticals Leadership Team
Elected by the shareholders, the Theseus Pharmaceuticals' board of directors comprises two types of representatives: Theseus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Theseus. The board's role is to monitor Theseus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Theseus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Theseus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Patrick LePore, Independent Director | ||
DPhil DPHIL, CoFounder Chairman | ||
Nachu Narasimhan, VP Safety | ||
Theodore Witek, Sr. VP of Corporate Partnerships, Clinical and Medical Affairs | ||
WeiSheng Huang, CoFounder Chemistry | ||
Catherine Friedman, Independent Director | ||
James Tyree, Independent Director | ||
Terrence Kearney, Independent Director | ||
Michael Faerm, Chief Bus. Officer and Sr. VP | ||
Barbara Duncan, Independent Director | ||
Paul Pepe, Independent Director | ||
George Abercrombie, Senior Vice President - Corporate Partnerships, Commercial | ||
Timothy Clackson, Pres CEO | ||
Len Rozamus, VP Operations | ||
Eric dEsparbes, CFO and Sr. VP | ||
Bradford Dahms, Chief officer | ||
Alicja Januszewicz, VP Culture | ||
Victor Rivera, VP CoFounder | ||
Benjamin Enerson, VP Affairs | ||
Michael Aguiar, CEO and President and Director | ||
Kristine CPA, VP Controller | ||
William Waltrip, Lead Independent Director | ||
MA DPHIL, CoFounder Chairman | ||
David MD, Chief Officer | ||
William Shakespeare, CoFounder RD |
Theseus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Theseus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.26 | |||
Return On Asset | -0.18 | |||
Current Valuation | (20.19 M) | |||
Shares Outstanding | 44.65 M | |||
Shares Owned By Insiders | 2.55 % | |||
Shares Owned By Institutions | 93.28 % | |||
Number Of Shares Shorted | 401.68 K | |||
Price To Earning | 737.67 X | |||
Price To Book | 0.81 X | |||
EBITDA | (66.44 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Theseus Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Theseus Pharmaceuticals' short interest history, or implied volatility extrapolated from Theseus Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in Theseus Stock
If you are still planning to invest in Theseus Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Theseus Pharmaceuticals' history and understand the potential risks before investing.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |